CME: Diabetic Retinopathy from Trials to Treatment (Web) Question Title * 1. Which of the following technologies was instrumental in defining an ischemic index, a leakage index, and a microaneurysm count in a study by Ehlers and colleagues? OCT OCT angiography Ultra widefield fluorescein angiography Fundus photography Question Title * 2. Which of the following studies will evaluate the impact of peripheral lesions and ultra widefield imaging on the risk of diabetic retinopathy progression? Protocol AA Protocol I Protocol S Protocol U Question Title * 3. According to DRCR Protocol T, which of the anti-VEGF agents had a slight advantage at 2 years in patients who started treatment with visual acuity of 20/50 or worse? Aflibercept Bevacizumab Ranibizumab None of the above Question Title * 4. What is the accepted definition of suboptimal response to anti-VEGF therapy in the retina community? No improvement after 2 injections No improvement after 3 injections No improvement after 5 injections There is no consensus Question Title * 5. Which intravitreal steroid has been shown to be most durable? Dexamethasone Fluocinolone Triamcinolone All are equally durable Question Title * 6. During Protocol S, how many injections did most eyes receive in 5 years? 1 to 3 4 to 9 10 to 15 >15 Question Title * 7. Which of the following therapies is being studied in Protocol W for preventing PDR or center-involving DME in eyes at high risk for these complications? Triamcinolone Dexamethasone Bevacizumab Aflibercept Question Title * 8. In the PANORAMA study of moderately severe to severe NPDR, what percentage of all eyes treated with aflibercept showed a 2-step improvement in DRSS from baseline? <20% Approximately 40% Approximately 60% >75% Next